Apyx Medical (APYX)
(Delayed Data from NSDQ)
$1.19 USD
-0.04 (-3.25%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.19 0.00 (0.00%) 6:36 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.19 USD
-0.04 (-3.25%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.19 0.00 (0.00%) 6:36 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Zacks News
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Reasons to Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's strong product portfolio raises optimism about the stock.
Butterfly Network's Stock Surges on iQ3 Device Launch in Europe
by Zacks Equity Research
Shares of BFLY gain almost 27% following the announcement of the launch of its latest handheld ultrasound device, Butterfly iQ3, in Europe.
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
by Zacks Equity Research
EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -5.56% and 4.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -30.77% and 1.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.96% and 8.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -22.22% and 6.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -46.15% and 1.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 1.47% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
biote Corp. (BTMD) delivered earnings and revenue surprises of -237.50% and 4.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Apyx Medical (APYX) This Year?
by Zacks Equity Research
Here is how Apyx Medical (APYX) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Apyx Medical (APYX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 8.33% and 4.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 16.67% and 0.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why You Should Add Humana (HUM) Stock to Your Portfolio Now
by Zacks Equity Research
Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.
Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now
by Zacks Equity Research
For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.
Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now
by Zacks Equity Research
The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.
The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights
by Zacks Equity Research
The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.
Is Abcam (ABCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Humana (HUM) Sees Insurance Costs at Upper Limit of Guidance
by Zacks Equity Research
Despite the rising demand for elective procedures, Humana (HUM) sticks to its earnings guidance.
Is Apyx Medical (APYX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apyx Medical (APYX) and Haemonetics (HAE) have performed compared to their sector so far this year.
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -60% and 12.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZimVie Inc. (ZIMV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ZimVie Inc. (ZIMV) delivered earnings and revenue surprises of 525% and 9.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?